Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5957
    +0.0008 (+0.13%)
     
  • NZD/EUR

    0.5547
    +0.0006 (+0.12%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.90
    +0.33 (+0.39%)
     
  • GOLD

    2,359.80
    +17.30 (+0.74%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,118.09
    +39.23 (+0.49%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,049.40
    +132.12 (+0.74%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.2850
    +0.7890 (+0.85%)
     

GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018

GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018

GlaxoSmithKline (GSK) segregates its business portfolio into three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare. As a British multinational company, GlaxoSmithKline reports its revenues in pounds sterling. The chart below compares GlaxoSmithKline’s EPS and revenues since the first quarter of 2017, as well as its estimates for the third quarter.